1h Free Analyst Time
The RNAi drug delivery market is forecasted to grow by USD 193.2 billion during 2023-2028, accelerating at a CAGR of 27.16% during the forecast period. The report on the RNAi drug delivery market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high target affinity and specificity of RNAi therapeutics, increasing research activities in pharmaceutical and biotechnology sectors, and increasing prevalence of neurological disorders.
The RNAi drug delivery market is segmented as below:
By Technology
- Nanoparticle drug delivery
- Pulmonary drug delivery
- Nucleic acid drug delivery
- Aptamer drug delivery
By Application
- Infectious diseases
- Oncology
- Cardiology
- Neurology
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the RNAi drug delivery market covers the following areas:
- RNAi drug delivery market sizing
- RNAi drug delivery market forecast
- RNAi drug delivery market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Technology
7 Market Segmentation by Application
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
360 degree market analysis
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global RNAi drug delivery market: Alnylam Pharmaceuticals Inc., Arbutus Biopharma Corp., Arrowhead Pharmaceuticals Inc., Bayer AG, Benitec Biopharma Inc., BioNTech SE, Bristol Myers Squibb Co., CureVac AG, e therapeutics PLC, F. Hoffmann La Roche Ltd., Novartis AG, Novo Nordisk AS, Phio Pharmaceuticals, Sanofi SA, Silence Therapeutics PLC, Silenseed Inc., siRNAgen Therapeutics Corp., Sirnaomics Inc., Sylentis S.A., Thermo Fisher Scientific Inc., and TransCode Therapeutics Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increasing R&D for RNAi therapy by market vendors."
According to the report, one of the major drivers for this market is the high target affinity and specificity of RNAi therapeutics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alnylam Pharmaceuticals Inc.
- Arbutus Biopharma Corp.
- Arrowhead Pharmaceuticals Inc.
- Bayer AG
- Benitec Biopharma Inc.
- BioNTech SE
- Bristol Myers Squibb Co.
- CureVac AG
- e therapeutics plc
- F. Hoffmann La Roche Ltd.
- Novartis AG
- Novo Nordisk AS
- Phio Pharmaceuticals
- Sanofi SA
- Silence Therapeutics plc
- Silenseed Inc.
- siRNAgen Therapeutics Corp.
- Sirnaomics Inc.
- Sylentis S.A.
- Thermo Fisher Scientific Inc.
- TransCode Therapeutics Inc.
